Table 2 Sociodemographic, clinical and psychosocial factors in patients with confirmed and refuted SAMSa in MUSE trial
Confirmed SAMS (N = 20, 28.1%) | Refuted SAMS (N = 51, 71.8%) | p-value | |
|---|---|---|---|
Socio-demographic factors | |||
Age, mean (SD) | 64.1 (11.0) | 63.2 (8.9) | 0.74 |
Female gender, n (%) | 7 (35) | 16 (31) | 0.77 |
Low educationb, n (%) | 12 (60) | 33 (65) | 0.71 |
Living alone, n (%) | 4 (20) | 8 (16) | 0.66 |
Clinical factors | |||
Myocardial infarction, n (%) | 17 (85) | 43 (84) | 0.94 |
> 1 previous coronary event, n (%) | 5 (25) | 21 (41) | 0.20 |
Low Density Lipoprotein Cholesterol (mmol/L), mean (SD) | 2.8 (1.2) | 2.3 (0.9) | 0.06 |
Rheumatic, inflammatory disease or arthrosis, n (%) | 8 (40) | 18 (35) | 0.71 |
No ongoing statin therapy at study start, n (%) | 5 (25) | 3 (6) | 0.02 |
Ezetemibe, n (%) | 3 (15) | 13 (26) | 0.34 |
Previous discontinuation due to side-effects, n (%) | 8 (40) | 28 (55) | 0.26 |
Psychological factors | |||
HADSc anxiety score, mean (SD) | 4.2 (4.0) | 5.4 (3.2) | 0.18 |
HADS depression score, mean (SD) | 3.3 (2.1) | 4.0 (2.8) | 0.31 |
Type D personality, SI-sumd, mean (SD) | 5.6 (6.0) | 7.3 (5.9) | 0.29 |
Type D personality, NA-sume, mean (SD) | 5.0 (5.1) | 6.9 (4.6) | 0.14 |
PWSQf worry scores, mean (SD) | 35.8 (11.5) | 39.3 (9.0) | 0.18 |
Bergen Insomnia scale, mean (SD) | 17.4 (12.1) | 17.9 (11.9) | 0.88 |
Beliefs about Medicines | |||
Necessity of statins, mean (SD) | 14.9 (2.5) | 17.5 (2.3) | < 0.01 |
Concerns of statins, mean (SD) | 14.6 (4.4) | 15.8 (4.7) | 0.34 |